Clinical trials
Advanced Malignant Tumors clinical trials
Below are recruiting advanced malignant tumors clinical trials, each written for real people, not researchers. We’re tracking 1,034 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06927349RecruitingPhase 1
A trial of BA1301 for advanced solid tumors
This trial tests a new drug, BA1301, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if BA1301 can help shrink or control the cancer.
Harbin, HeilongjiangAges 18–75 - NCT06130553RecruitingPhase 1/Phase 2
Study of AZD3470 for patients with MTAP-deficient advanced solid tumors
This trial tests an investigational drug called AZD3470, which blocks a protein called PRMT5, in people whose tumors lack a gene called MTAP. The goal is to see if the drug can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT05772455RecruitingPhase 1
Drug study for adults with solid tumors
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07467122RecruitingPhase 1
TCR-T cell therapy for MAGE-A4-positive sarcomas and other tumors
This trial tests a personalized cell therapy called TCR-T that targets a protein called MAGE-A4 on tumor cells. It is for people with advanced sarcomas or similar cancers that have not responded to standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Orange, CaliforniaAges 18 years+ - NCT06985355RecruitingPhase 1/Phase 2
Testing MHB046C injection for advanced solid tumors
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT06826040RecruitingPhase 1
A study of SKB445 for solid tumors
This trial tests a new drug called SKB445 for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if the drug is safe and effective for these patients.
Jinan, ShandongAges 18–75 - NCT07618260RecruitingPhase 1
Testing SIM0613 in advanced solid tumors
This is an early-stage trial testing a new drug called SIM0613 for advanced cancers that have spread or grown despite other treatments. The drug is designed to target cancer cells using a special delivery system.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06466265RecruitingPhase 1
Testing DNP002 for advanced solid tumors that have not responded to standard treatments
This trial tests a new drug called DNP002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if DNP002 is safe and can help shrink tumors or slow their growth.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT06963814RecruitingPhase 1
HC006 with a PD-1 inhibitor for advanced solid tumors
This trial tests a new drug called HC006 combined with a standard immunotherapy (PD-1 inhibitor) for people with advanced solid tumors. It aims to see if the combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06703177RecruitingPhase 1/Phase 2
Study of SHR-1826 combo for advanced solid tumors
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07434284RecruitingEarly Phase 1
Cell therapy plus immunotherapy for advanced gynecologic cancers
This trial is testing a new combination treatment for advanced gynecologic cancers (like ovarian, cervical, or endometrial) that have not responded to standard therapies. It combines a type of cell therapy (cCTL) with another immunotherapy to see if it can help patients who have few other options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07298772RecruitingPhase 1/Phase 2
Testing SHR-4375 with other therapies for solid tumors
This study tests a new drug called SHR-4375 combined with other cancer treatments for people with advanced solid tumors that haven't gotten better with standard care. The goal is to see if the combination is safe and works against the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06314373RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05719558RecruitingPhase 1
Study of ASP1002 for adults with solid tumors
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT03463954Recruiting
Laser treatment trial for small breast tumors
This trial tests a focused laser treatment (Novilase®) to destroy small, cancerous breast tumors while aiming to work with standard care. It may help people who have an early, localized tumor that can be clearly seen on imaging so doctors can guide the laser safely.
Duarte, CaliforniaAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Los Angeles, CaliforniaAges 18 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT06154291RecruitingPhase 1/Phase 2
XON7 for advanced or metastatic solid tumors
This trial tests an experimental drug called XON7 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if XON7 is safe and effective.
AnderlechtAges 18 years+ - NCT07070518RecruitingPhase 1/Phase 2
Study of GV20-0251 for advanced solid tumors
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT06650163RecruitingPhase 1
New imaging test for brain tumor surgery planning
This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant tumors?
- Yes. Clin2 currently lists 1,034 recruiting advanced malignant tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.